This category page catalogs biotechnology and pharmaceutical companies developing AMPK (AMP-activated protein kinase) activator therapies and broader energy metabolism modulators for Alzheimer's disease (AD). These approaches target the fundamental bioenergetic deficits, impaired autophagy, and mitochondrial dysfunction that are hallmarks of AD pathophysiology.
| Category | Companies |
|---|
| Direct AMPK Activators | Research stage |
| Indirect AMPK Activators (non-GLP-1) | 4 |
| Mitochondrial Function Modulators | 3 |
| Autophagy Enhancers | 2 |
| Metabolic/Bioenergetic | 4 |
| Phase 2 Trials | 2 |
| Phase 1 Trials | 2 |
| Preclinical/Discovery | 5+ |
AMPK is a central cellular energy sensor that coordinates metabolic homeostasis. In Alzheimer's disease, AMPK dysregulation contributes to:
- Impaired autophagy: Failure to clear amyloid-beta and tau aggregates
- Mitochondrial dysfunction: Reduced ATP production in energy-hungry neurons
- Neuroinflammation: AMPK regulates microglial inflammatory responses
- Synaptic failure: Energy deficits impair synaptic plasticity and function
- Insulin resistance: Linked to type 2 diabetes and AD risk
Activated AMPK phosphorylates key therapeutic targets: mTOR (autophagy), ULK1 (autophagy initiation), PGC-1α (mitochondrial biogenesis), and TFEB (lysosomal biogenesis). This cascade offers multiple mechanisms for disease modification beyond amyloid and tau targeting.
This page covers AMPK activators and energy metabolism approaches beyond GLP-1/SGLT2/metformin, which are catalogued in the AD Metabolic and GLP-1 Based Therapy Companies page. The focus here is on:
- Direct AMPK activators (research stage)
- Novel indirect AMPK activators (non-GLP-1 mechanisms)
- Mitochondrial-targeted therapies with AD programs
- Autophagy enhancers with AD programs
- Brain metabolic modulators beyond PPAR/GLP-1
While no direct AMPK activator has reached clinical trials for AD, several compound classes are in preclinical development:
| Compound |
Type |
Notes |
| Compound 991 |
Direct allosteric activator |
β1-selective, high potency |
| A-769662 |
Direct β1 activator |
Demonstrated in neurodegeneration models |
| PT1 |
Allosteric AMPK activator |
Brain-penetrant derivatives in development |
| Thienopyridone derivatives |
Direct AMPK activators |
CNS-optimized prodrugs |
| MK-8722 |
Pan-AMPK activator |
Excellent glucose homeostasis; cardiac hypertrophy concern |
Key Challenge: Brain penetration remains the primary hurdle. Current research focuses on:
- Prodrug approaches (improved BBB penetration)
- β1-isoform selectivity (reduce peripheral effects)
- Novel delivery systems (nanoparticles, intranasal)
Academic Programs: Multiple university labs are developing brain-penetrant AMPK activators, including programs at MIT, UC San Diego, and University of Pennsylvania.
¶ Berberine and Natural Compounds
- Focus: Berberine and botanical AMPK activators
- Mechanism: Indirect AMPK activation via gut microbiome modulation and mitochondrial complex I inhibition
- Status: Research/Phase 1
- Notes: Better CNS penetration than metformin; multi-target effects; GI side effects limit dosing
- Focus: Resveratrol and polyphenol AMPK activators
- Mechanism: SIRT1-mediated AMPK activation
- Status: Research
- Notes: Limited by poor bioavailability; nano-formulations in development
¶ Vandria SA
- Ticker: Private
- Headquarters: Geneva, Switzerland
- Focus: Mitochondrial quality control and cellular energetics
- Lead Candidate: VNA-318
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Phase 1
- Mechanism: Small molecule targeting mitochondrial dynamics, promoting mitophagy and neuronal survival
- Notes: Swiss biotech with expertise in mitochondrial biology; dual AD/PD programs; targets the PINK1/Parkin pathway for clearance of damaged mitochondria
- Page: Vandria SA
- Related: Mitochondrial Dysfunction, Mitochondrial Quality Control
- Ticker: Private
- Headquarters: Lexington, Massachusetts, USA
- Focus: Mitochondrial dynamics and DNA repair
- Mechanism: Targeting mitochondrial DNA repair mechanisms and dynamics (fusion/fission balance)
- Indication: Alzheimer's disease (exploratory)
- Stage: Discovery/Preclinical
- Notes: Emerging program in neurodegeneration; core platform in cancer could translate to AD
- Related: Mitochondrial Dysfunction
- Ticker: NASDAQ: CLNN
- Headquarters: Salt Lake City, Utah, USA
- Focus: Nanotherapeutic approach to cellular energy impairment
- Lead Candidate: CNM-Au8 (gold nanocrystals)
- Indication: ALS (primary), Parkinson's disease (primary), Alzheimer's disease (exploratory)
- Stage: Phase 2 (PD, ALS); Phase 1 (AD exploratory)
- Mechanism: Gold nanocrystals catalyze redox reactions, supporting mitochondrial function, reducing oxidative stress, and enhancing neuronal survival
- Notes: CNM-Au8 (formerly CNM-201) has shown efficacy in animal models of PD and ALS; ACTIVE clinical trial in PD; exploratory AD program underway; indirect AMPK activation through improved bioenergetics
- Page: Clene Nanomedicine
- Related: Mitochondrial Dysfunction, Oxidative Stress
- Ticker: Private
- Headquarters: San Francisco, California, USA
- Focus: Autophagy and cellular clearance
- Lead Candidate: RB-001
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: Autophagy enhancement to clear protein aggregates (amyloid-beta, tau); also developing senolytic approaches
- Notes: Founded by Sam Altman and others; significant funding; addresses fundamental protein clearance deficit in AD; Phase 1 safety data expected 2025
- Page: Retro Biosciences
- Related: Autophagy-Lysosomal Pathway, AMPK Signaling Pathway
- Ticker: Private
- Focus: Small molecule autophagy enhancers
- Mechanism: ULK1 activation, mTOR-independent autophagy pathways
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Discovery/Preclinical
- Notes: Academic spin-out; novel mechanism targeting TFEB nuclear translocation
- Related: Autophagy-Lysosomal Pathway
- Ticker: Private
- Headquarters: Research Triangle Park, North Carolina, USA
- Focus: Metabolic dysfunction in AD
- Lead Candidate: T3D-959 (PPAR δ/γ dual agonist)
- Indication: Alzheimer's disease
- Stage: Phase 2 (PIONEER trial)
- Mechanism: Improves brain glucose uptake, mitochondrial function, reduces neuroinflammation; secondary AMPK activation through improved insulin sensitivity
- Notes: FDA Fast Track designation; first-in-class metabolic therapy for AD; primary endpoint in PIONEER trial
- Page: T3D Therapeutics
- Related: Brain Metabolic Dysfunction, PPAR Signaling
- Ticker: NASDAQ: ATHA
- Headquarters: Bothell, Washington, USA
- Focus: Neurotrophic factor enhancement and metabolic support
- Lead Candidate: Fosramutstat (ATH-102)
- Indication: Alzheimer's disease
- Stage: Phase 1
- Mechanism: Small molecule that increases HGF/c-Met signaling, enhancing neurogenesis, synaptic function, and neuronal metabolism; improves mitochondrial function
- Notes: HGF (hepatocyte growth factor) system supports neuronal repair and metabolic function; positive Phase 1 interim data; Phase 2 planned
- Page: Athira Pharma
- Related: Neurotrophic Factor Signaling, Neurogenesis
- Ticker: Private
- Headquarters: Singapore
- Focus: Cerebral blood flow and metabolic enhancement
- Lead Candidate: CPP-115 (GABA transaminase inhibitor)
- Indication: Alzheimer's disease
- Stage: Preclinical
- Mechanism: GABA transaminase inhibition improves energy metabolism in neurons; targets vascular function alongside metabolism
- Notes: Singapore-based company with strong metabolic focus; explores intersection of vascular dysfunction and energy metabolism in AD
- Related: Neurovascular Coupling, Cerebral Blood Flow
- Ticker: NYSE: BHVN (acquired by Pfizer)
- Headquarters: New Haven, Connecticut, USA
- Focus: Metal binding, metabolic approaches, TRPM2 modulators
- Lead Candidates: Troriluzole (BHV-4157), BHV-7000 (TRPM2 modulator)
- Indication: Alzheimer's disease
- Stage: Phase 2 (Troriluzole); Preclinical (TRPM2)
- Mechanism: Troriluzole: sigma-1 agonist with metal chelation properties and metabolic support; TRPM2: calcium channel modulation supporting neuronal metabolism
- Notes: Pfizer acquisition expands resources; sigma-1 receptor localization to mitochondria-associated membranes links to metabolic effects; Phase 2 data anticipated 2025
- Page: Biohaven
- Related: Metal Homeostasis, Sigma-1 Receptor
¶ Emerging and Early-Stage Programs
- Ticker: Private (Alphabet subsidiary)
- Focus: Longevity and metabolic interventions
- Notes: Exploring AMPK-activating approaches; significant resources; academic-style research model
- Related: Calico
Multiple academic programs are developing AMPK-targeting and energy metabolism approaches for AD:
| Institution |
Approach |
Status |
| UC San Diego |
Novel brain-penetrant AMPK activators |
Preclinical |
| University of Michigan |
Mitochondrial-targeted peptides |
Research |
| Columbia University |
TFEB activators for autophagy |
Research |
| Scripps Research |
Natural product AMPK modulators |
Research |
| Company |
Drug/Candidate |
Mechanism |
Phase |
Indication |
| T3D Therapeutics |
T3D-959 |
PPAR δ/γ agonist (metabolic) |
Phase 2 |
AD |
| Retro Biosciences |
RB-001 |
Autophagy enhancement |
Phase 1 |
AD |
| Vandria SA |
VNA-318 |
Mitochondrial modulator |
Phase 1 |
AD/PD |
| Clene Nanomedicine |
CNM-Au8 |
Nanocatalytic bioenergetic |
Phase 2 |
PD/ALS; AD exploratory |
| Athira Pharma |
Fosramutstat (ATH-102) |
HGF/c-Met agonist (metabolic) |
Phase 1 |
AD |
| Biohaven |
Troriluzole (BHV-4157) |
Sigma-1/metal chelation |
Phase 2 |
AD |
| Biohaven |
BHV-7000 |
TRPM2 calcium channel |
Preclinical |
AD |
| Cerecin |
CPP-115 |
GABA transaminase inhibitor |
Preclinical |
AD |
| Various |
Direct AMPK agonists |
Direct AMPK activation |
Research |
AD/PD |
¶ Key Challenges and Opportunities
- Blood-brain barrier penetration: Many AMPK activators have poor CNS exposure
- Isoform selectivity: Non-selective AMPK activation causes peripheral adverse effects
- Dose optimization: Chronic vs. acute activation may require different approaches
- Biomarkers: Need pharmacodynamic markers for AMPK activation in brain tissue
- Mechanism complexity: AMPK has both protective and pathological roles depending on context
- Exercise mimetics: Novel compounds that recapitulate AMPK-dependent exercise benefits
- Combination approaches: AMPK activation + autophagy enhancement + mitochondrial support
- Stage-specific targeting: Pre-symptomatic (preventive) vs. symptomatic (therapeutic)
- Biomarker development: p-AMPK, PGC-1α, LC3 as pharmacodynamic endpoints
- Repurposing: Existing metabolic drugs with AMPK activity (berberine, salicylates)